That was a huge screw up on my part folks... I actually had a buy order in at $114 and puled it on a bad DOW day, this was after the stk corrected from $122- I had played it perfectly but failed to buy back in. I've got a lot of explaining to do to my shareholders. Luckily most all of them are dead.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an alternative browser.
You should upgrade or use an alternative browser.
Ideas For Now-
- Thread starter stonedinvestor
- Start date
Alright here we go one more for you:
Way back in May a little bit of news came out--
U.S. military scientists design new early COVID-19 test, Guardian says 05/01
Scientists working for the U.S. military have designed a new coronavirus test that could possibly identify carriers of the virus before they become infectious and spread the virus, The Guardian's Giles Tremlett reports. Project coordinators are hoping that the blood-based test will be able to detect the virus' presence as soon as 24 hours after infection, Tremlett says. The test could open up the possibility of isolating pre-infectious cases and shutting down transmission claims, the author says, noting that it could also dramatically lower quarantine periods for those exposed to COVID-19 spreaders. "It could have exceptional demand," said Fluidigm CEO Chris Linthwaite, who believes frequent testing can help manage workforces as they return to places of business. Fluidigm is part of the testing project, according to The Guardian.
// So no surprise the military way back then developed something unique for Covid testing bit of a surprise why the administration has not pushed it out to the public. Did it not work? Or are they just disfunctional?
+ All of these insitutions have been testing with Fluidigm's reagents
Institutions participating in the study are Brigham and Women's Hospital; University Hospitals Case Medical Center; University of California, Los Angeles Department of Medicine; University of California, San Francisco School of Medicine; Drexel University College of Medicine; Emory University School of Medicine; Icahn School of Medicine at Mount Sinai; Oregon Health & Science University; Stanford Medicine's Sean N. Parker Center for Allergy & Asthma Research; and Yale School of Medicine.
+GnomeDX files for FDA EUA for RT-PCR COVID-19 test 07/20 FLDM Fluidigm Corporation announced that Gnome Diagnostics is utilizing Fluidigm microfluidics technology and reagents in a test developed to detect the SARS-CoV-2 virus, which causes COVID-19. The Rapid Turnaround Real-Time RT-PCR COVID-19 Test, which can be performed via oropharyngeal, nasopharyngeal and nasal swab, is intended to meet growing testing needs for patients, health care workers and other critical populations across central Ohio. GnomeDX has filed for Emergency Use Authorization for its extraction-free GnomeDX RT-PCR COVID-19 Test from the U.S. Food and Drug Administration. GnomeDX is a high-complexity lab certified under the Clinical Laboratory Improvement Amendments in the United States and eligible under FDA guidance to create its own diagnostic tests for COVID-19. GnomeDX has validated a workflow using assays developed by the Centers for Disease Control and Prevention designed to be run on the Fluidigm Biomark HD system. Because sample collection methods for the test include oropharyngeal and nasal swabs, it does not require invasive nasopharyngeal collection. <-----
COVID-19 testing on the Biomark HD platform provides throughput and cost advantages that reduce the impact of capacity-constrained supply chains. Fluidigm's microfluidics technology enables processing of more samples per batch and uses a fraction of expensive testing reagents per sample as compared to more traditional, microwell plate-based PCR technology.
In early June, Fluidigm filed for Emergency Use Authorization with the FDA for an extraction-free saliva-based test to detect the SARS-CoV-2 virus. The test was developed in collaboration with scientists at the McDonnell Genome Institute and the Department of Genetics at the Washington University School of Medicine in St. Louis. With respect to the Fluidigm test, Fluidigm has filed for Emergency Use Authorization with the FDA. The test has been validated by Fluidigm, but the FDA's independent review of this validation is pending. The FDA may require additional data, validation and/or testing, and may not ultimately provide authorization for EUA requests. An EUA, if granted, does not constitute FDA clearance or approval, but would allow use by authorized laboratories only while the EUA is in effect.
OK SO TIMELINE -WISE IT'S BEEN A MONTH WITH ALL THOSE STUDIES.... You would think the FDA would OK the EUA it's not an approval after all.. and the stock may move on that. When I researched this stock originally it was because we were in the midst of a panic and the re agents were in short supply thanks to China... So this is an important step if it works to eliminate or reduce those reagents and on top of that it's saliva you don't have to go up the nose.... Certainly A Ticking Time Bomb either way!!! I make no judgement except to say those seem like pretty good study partners and everyone this small company works with seems at the upper level of what they do... perhaps this is the unknown testing play STILL to play out.
WATCH FLDM Now $5.61 This is $1 higher than when I assumed coverage! But it's been a slow dollar....
I think IIPR & FLDM are my Buys))))
I'll wait on Van's assessment of an uptrend target for GRWG....
~stoney
Way back in May a little bit of news came out--
U.S. military scientists design new early COVID-19 test, Guardian says 05/01
Scientists working for the U.S. military have designed a new coronavirus test that could possibly identify carriers of the virus before they become infectious and spread the virus, The Guardian's Giles Tremlett reports. Project coordinators are hoping that the blood-based test will be able to detect the virus' presence as soon as 24 hours after infection, Tremlett says. The test could open up the possibility of isolating pre-infectious cases and shutting down transmission claims, the author says, noting that it could also dramatically lower quarantine periods for those exposed to COVID-19 spreaders. "It could have exceptional demand," said Fluidigm CEO Chris Linthwaite, who believes frequent testing can help manage workforces as they return to places of business. Fluidigm is part of the testing project, according to The Guardian.
// So no surprise the military way back then developed something unique for Covid testing bit of a surprise why the administration has not pushed it out to the public. Did it not work? Or are they just disfunctional?
+ All of these insitutions have been testing with Fluidigm's reagents
Institutions participating in the study are Brigham and Women's Hospital; University Hospitals Case Medical Center; University of California, Los Angeles Department of Medicine; University of California, San Francisco School of Medicine; Drexel University College of Medicine; Emory University School of Medicine; Icahn School of Medicine at Mount Sinai; Oregon Health & Science University; Stanford Medicine's Sean N. Parker Center for Allergy & Asthma Research; and Yale School of Medicine.
+GnomeDX files for FDA EUA for RT-PCR COVID-19 test 07/20 FLDM Fluidigm Corporation announced that Gnome Diagnostics is utilizing Fluidigm microfluidics technology and reagents in a test developed to detect the SARS-CoV-2 virus, which causes COVID-19. The Rapid Turnaround Real-Time RT-PCR COVID-19 Test, which can be performed via oropharyngeal, nasopharyngeal and nasal swab, is intended to meet growing testing needs for patients, health care workers and other critical populations across central Ohio. GnomeDX has filed for Emergency Use Authorization for its extraction-free GnomeDX RT-PCR COVID-19 Test from the U.S. Food and Drug Administration. GnomeDX is a high-complexity lab certified under the Clinical Laboratory Improvement Amendments in the United States and eligible under FDA guidance to create its own diagnostic tests for COVID-19. GnomeDX has validated a workflow using assays developed by the Centers for Disease Control and Prevention designed to be run on the Fluidigm Biomark HD system. Because sample collection methods for the test include oropharyngeal and nasal swabs, it does not require invasive nasopharyngeal collection. <-----
COVID-19 testing on the Biomark HD platform provides throughput and cost advantages that reduce the impact of capacity-constrained supply chains. Fluidigm's microfluidics technology enables processing of more samples per batch and uses a fraction of expensive testing reagents per sample as compared to more traditional, microwell plate-based PCR technology.
In early June, Fluidigm filed for Emergency Use Authorization with the FDA for an extraction-free saliva-based test to detect the SARS-CoV-2 virus. The test was developed in collaboration with scientists at the McDonnell Genome Institute and the Department of Genetics at the Washington University School of Medicine in St. Louis. With respect to the Fluidigm test, Fluidigm has filed for Emergency Use Authorization with the FDA. The test has been validated by Fluidigm, but the FDA's independent review of this validation is pending. The FDA may require additional data, validation and/or testing, and may not ultimately provide authorization for EUA requests. An EUA, if granted, does not constitute FDA clearance or approval, but would allow use by authorized laboratories only while the EUA is in effect.
OK SO TIMELINE -WISE IT'S BEEN A MONTH WITH ALL THOSE STUDIES.... You would think the FDA would OK the EUA it's not an approval after all.. and the stock may move on that. When I researched this stock originally it was because we were in the midst of a panic and the re agents were in short supply thanks to China... So this is an important step if it works to eliminate or reduce those reagents and on top of that it's saliva you don't have to go up the nose.... Certainly A Ticking Time Bomb either way!!! I make no judgement except to say those seem like pretty good study partners and everyone this small company works with seems at the upper level of what they do... perhaps this is the unknown testing play STILL to play out.
WATCH FLDM Now $5.61 This is $1 higher than when I assumed coverage! But it's been a slow dollar....
I think IIPR & FLDM are my Buys))))
I'll wait on Van's assessment of an uptrend target for GRWG....
~stoney
HERMAN CAIN DIES OF COVID.
Wow. This could shake up things. Maybe a bit of a reality check.
Wow. This could shake up things. Maybe a bit of a reality check.
That 136K shares, thats old. They were back in June when the price was in that range. Here:Update-
I don't get it why did they sell at $7.32 when the stock is $8.68?
- Beneficial owner of GrowGeneration (GRWG) Merida Capital sold 136,032 shares of company stock at $7.32 per share for a total transaction value of $996,230
Targets are only $9 / What do you think Van>... run your RSI through that <MACD and get back to me ASAP ! ~si
https://www.sec.gov/Archives/edgar/data/1604868/000101359420000621/xslF345X03/form4.xml
It might keep running Stoney. I wonder why it jumped today, was there news? I'd let it ride. Keep an eye on the volume though for the next week, if there's a spike above 2M shares its gonna go ham. Somebody must know something, because a 5% move on a day like today is pretty odd in the absence of any news. They might be orchestrating a Kodak moment, on a lesser scale of course.
I'm OUT!!! VAN made 30%......... I'm free balling here big mistake this is when one makes huge mistakes when they reach because another idea worked but Folks I'm taking a chance on FLDM back in a sec...
Folks watch a portfolio manager blow himself up./.. really do not act like this.
What happens is I go through my old notebooks and I re look at some ideas what worked what didn't and near all my scriblings on HOLX I have a little tidbit on these other guys.... FLDM. Completely on the come... This is new breaking ground stuff always super risky.
But I've been bit by the testing bug.... Fluidigm HAS BEEN ADDEED TO THE IDEAS FOR NOW PORTFOLIO!!!! NOTICE A COUPLE 30K BUYS THERE INTERDAY VAN....... COME ON!!!!
LETS DO THIS!!!!$$5.70
What happens is I go through my old notebooks and I re look at some ideas what worked what didn't and near all my scriblings on HOLX I have a little tidbit on these other guys.... FLDM. Completely on the come... This is new breaking ground stuff always super risky.
But I've been bit by the testing bug.... Fluidigm HAS BEEN ADDEED TO THE IDEAS FOR NOW PORTFOLIO!!!! NOTICE A COUPLE 30K BUYS THERE INTERDAY VAN....... COME ON!!!!
LETS DO THIS!!!!$$5.70
@stonedinvestor , @vanzandt
Do what you will with this Vegas info.
WYNN is discussing closure/bankruptcy.
My info comes from a long time friend in overseas marketing. Not quite C-suite, but very close.
CES 2021 going 100% virtual is only one, but is a BIG catalyst.
And that is affecting every (major) hotel in Vegas as well. Heads up.
As of this post, there is no official news afaik, although phone calls to those needing to know are being made.
Vegas is not a good bet!!
Do what you will with this Vegas info.
WYNN is discussing closure/bankruptcy.
My info comes from a long time friend in overseas marketing. Not quite C-suite, but very close.
CES 2021 going 100% virtual is only one, but is a BIG catalyst.
And that is affecting every (major) hotel in Vegas as well. Heads up.
As of this post, there is no official news afaik, although phone calls to those needing to know are being made.
Vegas is not a good bet!!
That would be great news for El Dorado!
Ok we have a problem a Mr Cooper problem how did we let this one get away... remember Leon Cooperman talking about this stock and it's real value~1! Damn that cat is smart why didn't we just buy it
Ok we have a problem a Mr Cooper problem how did we let this one get away... remember Leon Cooperman talking about this stock and it's real value~1! Damn that cat is smart why didn't we just buy it
@stonedinvestor , @vanzandt
Do what you will with this Vegas info.
WYNN is discussing closure/bankruptcy.
My info comes from a long time friend in overseas marketing. Not quite C-suite, but very close.
CES 2021 going 100% virtual is only one, but is a BIG catalyst.
And that is affecting every (major) hotel in Vegas as well. Heads up.
As of this post, there is no official news afaik, although phone calls to those needing to know are being made.
Vegas is not a good bet!!
Wow. Man I don't see WYNN going t/u... but I guess anything can happen huh? We'll have to and see if Stevie's ex starts dumping all those shares he gave her.
Its funny you brought that up though, I was doing some digging yesterday on a backdoor short... not Vegas, well some Vegas, but mainly all these other casino's across the country. There's a reit that owns a bunch of the actual properties, and they lease them out to Eldorado and Penn.
$GLPI
I had never heard of them.
https://en.wikipedia.org/wiki/Gaming_and_Leisure_Properties
I was surfing the websites of a bunch of these various Casino's yesterday to see if they were open... many are slated to actually close again. And even with them being open, the table games are at 50% seating and the poker rooms appear to all be closed. Slots are 6' so I would imagine many are turned off. That's gotta sting. So Penn and Eldorado... I'm sure they are going to have to re-negotiate these leases.
I didn't post it because it doesn't seem like a sure thing, but still....
Hold on Van where was COOP when we were talking about it do a SEARCH-- This is distressing...
dang-- Took off from $14.20 yesterday....
1 month $12-$15...!!!!! This is the worst part about investing. Alright stock was up 13% in two days on no news and now the upgrade. Suspicious. $24 PT Barclays
dang-- Took off from $14.20 yesterday....
1 month $12-$15...!!!!! This is the worst part about investing. Alright stock was up 13% in two days on no news and now the upgrade. Suspicious. $24 PT Barclays